U.S. FDA Approves Breyanzi for Adults with Rel... - CLL Support
U.S. FDA Approves Breyanzi for Adults with Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL)
You need to be a member of this community to see this post.
5 Replies
You need to be a member of this community to see hidden responses.
Not what you're looking for?
You may also like...
Ibrutinib Slow but steady foreward movement.
Slowly things move forwards…
New Marketing Authorisation Application Submitted to EMA for...
CAR T was just approved for Relapsed/Refractory CLL/SLL ( Potentially 20% CURE rate)
What are your thoughts/suggestions/comments?
Thank you,
Pat...
More CAR-T: Looking Back to Go Forward in CAR-T Cell Therapy in R/R CLL
Long-term data from a phase 1 study investigating anti-CD19 chimeric antigen receptor (CAR) T-cell...
Duvelisib Dosing Modification Does Not Compromise Efficacy in Heavily Pretreated CLL/SLL
Reducing or interrupting duvelisib (Copiktra) treatment does not increase toxicity or reduce...
ATTENTION CLL + SLL PATIENTS AND CAREGIVERS
Lymphoma Canada and the CLL Patient Advocacy Group (CLLPAG) is preparing a submission for the...
EHA 2022: Outcomes Following Treatment With a Covalent BTK and BCL2 Inhibitor
News about V+O and Acalabrutinib from EHA
FDA APPROVAL FOR ZANUBRUTINIB
Early Intervention for CLL
